key: cord-1001821-41igg68l authors: Türsen, Ümit; Türsen, Belma; Lotti, Torello title: Cutaneous sıde‐effects of the potential COVID‐19 drugs date: 2020-05-22 journal: Dermatol Ther DOI: 10.1111/dth.13476 sha: 87ae992ff24eac27487e562d02f5b29ff65d89f7 doc_id: 1001821 cord_uid: 41igg68l COVID‐19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon‐beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side‐effects of these drugs. COVID-19 infection has rapidly spread across the world since its identification at the end of 2019. There are still no available evidencebased therapies for this infection. 1 We present the information on potential cutaneous adverse events of anti-COVID-19 drugs on dermatology practice. We use chloroquine and hydroxychloroquine for the treatment of discoid lupus erythematosus and understand its relative safety. Hydroxychloroquine and chloroquine have antiviral activity against COVID-19 in vitro and small-uncontrolled clinical studies with limited and inconclusive results. In COVID-19, a small non-randomized study from France indicated some benefits with serious methodological flaws, and a follow-up study still lacked a control group. However, another very small, randomized study from China in patients with mild to moderate COVID-19 and also a quasirandomized study from the United States found no difference in the recovery rates. 2, 3 Cutaneous adverse events of antimalarials include cutaneous eruptions such as acute generalized exanthematous pustulosis, urticaria, pruritus, dry skin, rashes, flares of psoriasis and exfoliating lesions, Stevens-Johnson-like syndrome, mucocutaneous dyspigmentation, alopecia and bleaching of hair. 4 We also have to do the differential diagnosis of the skin manifestations of COVID-19 infection such as erythematous rash, petechia, urticaria, and vesicles in patients with COVID-19 5 who are using antimalarials. Due to the remarkable pharmacokinetics and efficacy, azithromycin with immunomodulatory and anti-inflammatory properties is wellestablished as a potent treatment for some skin diseases such as rosacea, psoriasis, and synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. 6 Combining hydroxychloroquine with the antibiotic azithromycin has also been associated with positive patient outcomes according to the low-powered France study. 7 Whether this results in better clinical outcomes is still being debated. Skin adverse events of azithromycin are cutaneous severe skin reaction associated fever, angioedema, burning in eyes, skin pain, generalized red or purple skin rashes, blistering, skin peeling, toxic pustuloderma, anaphylaxis, DRESS syndrome, cutaneous leukocytoclastic vasculitis, and fixed drug eruptions. 8 These eruptions occur in also COVID infections' findings. Colchicine has been used to treat various dermatologic diseases, some of which are quite seldom, which include Behçet's disease, epidermolysis bullosa acquisita, recurrent oral aphthosis, cutaneous vasculitis, chronic urticaria and Sweet syndrome for its anti-neutrophilic immunomodulatory effect. In the last clinical trial called COLCORONA (Colchicine COVID-19 Trial), colchicine is being used to reduce the inflammatory reaction caused by COVID-19 that can lead to pulmonary involvement, organ failure, and death. It will be used for its anti-inflammatory and anti-cytokine storm effects when treating COVID-19. 9 Skin side-effects of colchicine include diffuse, blanchable, violaceous, morbilliform rash, lichenoid drug eruption, alopecia, toxic epidermal necrolysis-like reaction, erythema-bullous, and erythema-nodosum-like lesions. 10, 11 5 | REMDESIVIR Remdesivir shuts down viral replication by inhibiting a key viral enzyme, the RNA polymerase. The drug, which is given intravenously, has been used in hundreds of COVID-19 patients in China, the United States, and Europe as clinical studies. One of the most common adverse events is skin rashes. 12 6 | OSELTAMIVIR/FAVIPIRAVIR/ UMIFENOVIR Favipiravir is a nucleoside analog that is well-known as a broad-spectrum antiviral drug with a lower side-effects profile. 13 Oseltamivir can cause Stevens-Johnson syndrome/toxic epidermal necrolysis, angioedema allergic, or idiosyncratic cutaneous drug reactions. 14, 15 Umifenovir inhibits membrane fusion of the viral envelope and S protein/ACE2 interaction. It is approved for influenza treatment in Russia and China and a randomized-controlled trial of umifenovir is still going on the anti-COVID-19 agent. There are no reports on the skin reaction of umifenovir. 16 It is a broad antiviral against respiratory viruses such as influenza A and B viruses and parainfluenza 1 virus. Ribavirin, telbivudine, vitamin B12, nicotinamide combinations are proposed for COVID-19 treatment. 9 Dermatological side effects of ribavirin include acneiform eruptions, alopecia, localized scleroderma, maculopapular, and eczematous lesions, skin dryness, pruritus, and rash. 17 Interferon is a broadspectrum antiviral via interaction with the toll-like receptors and it can inhibit the viral replication. There is an ongoing study to evaluate the efficacy and safety of interferon-α + ribavirin combination. 9 Cutaneous side-effects of interferons are injection site reactions, psoriasis, eczematous drug reactions, alopecia, sarcoidosis, lupus, cutaneous vasculitic lesions, psoriasis, and lichenoid drug reactions. These adverse events are estimated to occur as 13% to 23%. 18,19 We use these agents for HIV diseases and they also have anticoronavirus activity via inhibition of 3-chymotrypsin-like protease. There are mostly case reports and small retrospective non-randomized cohort studies lopinavir and ritonavir as anti-COVID-19 drugs. Although additional randomized controlled trials of these agents are ongoing, the current findings suggest a limited effect for antiretrovirals in COVID-19 treatment. In vitro studies indicated activities of darunavir, protease inhibitors, and integrase strand transfer inhibitors against COVID-19. 20 It has broad antiviral and antihelmintic activity with lesser side-effect risks. In vitro studies suggest that nitazoxanide shows anti-COVID19 and immunomodulatory activities. 9 Hair loss, pruritus, and allergic skin reactions such as urticaria, rash, redness are cutaneous skin sideeffects. 25 Camostat mesylate can inhibit host serine protease as the anti-COVID-19 agent. It is an approved drug in Japan for pancreatitis. Rash, itch, yellow discoloration of the skin or conjunctiva, and purpura are the skin effects of this drug. 26 Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease and this drug can reduce mucus viscosity in the lungs and also improve the clearance of secretions. It has no serious side-effects on the skin and phase studies also are still going on as anti-COVID19 agent. 27 These therapies are steroids, anti-cytokine or immunomodulatory agents, and immunoglobulin therapy. Corticosteroids have anti-inflammatory functions and they can suppress the inflammation during COVID-19 associated acute respiratory distress syndrome. Short term (3-5 days) and very low doses (methylprednisolone 1-2 mg/kg/day) are recommended. 9 Skin side-effects of steroids include pruritus, burning, stinging, folliculitis, dryness, acneiform eruptions, skin atrophy, telangiectasia, erythema, edema, fissures, urticaria, disease exacerbation, acne, papulopustular lesions, hirsutism, and stria. 28 Artificial intelligence predicts that Janus kinase (JAK) inhibitors like baricitinib may block viral entry into pneumocytes in COVID-19 infection. 29 Higher TNF-α levels have been found in patients with COVID-19 and these correlate with disease severity. It has been suggested that anti-TNF-α treatment of COVID-19 may be a potential option, and a randomized, controlled trial of adalimumab has been started. 40 Cutaneous side-effects of anti-TNFs include infusion and injection site reactions, psoriasis and psoriasiform-like lesions, lupus-like syndromes, cutaneous vasculitis, cutaneous infections, eczematous reactions, lichenoid eruptions, granulomatous reactions, cutaneous lymphoma, epithelial skin cancers or melanoma. 39 High-dose intravenous immunoglobulin (IVIG) collected from recovered Coronavirus-19 patients may protect against COVID-19 and strengthen the immune system of new severe and treatment-resistant patients. 41, 42 Skin adverse events of IVIG treatments include anaphylactic reaction, facial vasculitic rash, urticaria, maculopapular rashes, petechiae, eczema, erythema multiforme, and alopecia. 43, 44 The inhibition of CD200-CD200R1 and anti-PD agents have positive effects on coronavirus infection, restoring IFN production, and increasing virus clearance. Studies on checkpoint inhibitors are ongoing in CoViD-19 patients. 45 Rash, pruritus, xerosis, alopecia, stomatitis, urticaria, photosensitivity reaction, hyperhidrosis, vitiligo, skin exfoliation, hair color changes, impaired skin wound healing, periungual pyogenic granuloma-like lesions, sarcoidosis-like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis are the cutaneous adverse events of checkpoints inhibitors. 46 and helpful for the differential diagnosis. 48 We should obtain the his- (Table 1) . 41 After examining all the treatments, although potentiality effective against COVID-19, we may start them one by one required by the safest and the most effective appropriate drug to minimize the development of the cutaneous drug eruptions and for the easy diagnosis. The authors declare no conflict of interest. Pattern of early human-to-human transmission of Wuhan A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Clinical outcomes of hydroxichloroquine in hospitalized patients with COVID-19: a quasirandomized comparative study Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón Cutaneous manifestations in COVID-19: a first perspective Cochrane skin group interventions for rosacea Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Azithromycin induced bullous fixed drug eruption Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Colchicine intoxication diagnosed in a skin biopsy: a case report Lichenoid drug eruption induced by colchicine: case report Compassionate use of Remdesivir for patients with severe Covid-19 Associations between immunesuppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. Medicine (Baltimore) Tongue swelling in association with oseltamivir (Tamiflu) Favipiravir versus Arbidol for COVID-19: a randomized clinical trial Acneiform eruptions: An unusual dermatological side effect of ribavirin Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: a multicenter prospective cohort study Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease Cutaneous adverse reactions to highly antiretroviral therapy in HIV-positive patients SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor Cutaneous toxicities of antiretroviral therapy for HIV: part I. lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors Adverse effects of antiretroviral treatment Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial Inhibition of Protease-Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways Dornase alfa for cystic fibrosis Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Baricitinib-a januase kinase inhibitor-not an ideal option for management of COVID 19 Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis Persistence and adherence during the first six months of tocilizumab treatment among rheumatoid arthritis patients in routine clinical practice in Greece. Results from the single arm REMISSION II study Psoriasiform dermatitis developing during treatment of juvenile idiopathic arthritis with tocilizumab Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial Anakinra in children and adults with Still's disease Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes The use of Janus kinase inhibitors in the time of SARS-CoV-2 Oral Tofacitinib: contemporary appraisal of its role in dermatology Biologic agent-associated cutaneous adverse events: a single center experience A review of SARS-CoV-2 and the ongoing clinical trials High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019 Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Alopecia universalis as a side effect of pegylated interferon α-r combination therapy for hepatitis C: a rare case report Complications of intravenous immune globulin treatment in neurologic disease The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor Cutaneous manifestations in COVID-19: a new contribution Cutaneous Drug Eruptions in Pediatrics-A Primer Adverse cutaneous reactions to influenza vaccinations and chemotherapy How to cite this article: Türsen Ü, Türsen B, Lotti T. Cutaneous sıde-effects of the potential COVID-19 drugs